Table 3.
Patient characteristics, diagnoses and outcomes.
| RVVC | Non-RVVC | Total | p Value | |
|---|---|---|---|---|
| Primary diagnosis, n (%) | 57 (73) | 21 (28) | 78 (100) | - |
| Median age (range) | 39 (20–73) | 29 (17–76) | 37 (17–76) | 0.0754 |
| Catalyst, n (%) | ||||
| Antibiotic | 13 (11) | 4 (20) | 17 (23) | >0.9999 |
| Menarche | 4 (7) | 2 (10) | 6 (8) | 0.6577 |
| Menopause | 5 (9) | 0 (0) | 5 (6) | 0.3160 |
| Pregnancy | 6 (22) | 2 (10) | 8 (10) | >0.9999 |
| Use of hormonal agents, n (%) | 17 (30) | 6 (29) | 23 (29) | >0.9999 |
| Symptoms, n (%) | ||||
| Discharge | 44 (79) | 13 (62) | 57 (73) | 0.2493 |
| Itch | 42 (75) | 13 (62) | 55 (71) | 0.4022 |
| Soreness | 28 (50) | 7 (33) | 35 (45) | 0.3052 |
| Burning | 14 (25) | 3 (14) | 17 (22) | 0.5369 |
| Dyspareunia | 12 (21) | 5 (24) | 17 (22) | 0.7664 |
| Dryness | 8 (14) | 3 (14) | 9 (12) | >0.9999 |
| Secondary diagnoses, n (%) | ||||
| Bacterial vaginosis | 10 (18) | 4 (19) | 14 (18) | - |
| Vulvodynia | 10 (18) | 6 (29) | 16 (21) | - |
| Vulval eczema/dermatitis | 9 (16) | 7 (33) | 16 (21) | - |
| Other | 5 (9) | 3 (14) | 8 (10) | - |
| MBL deficiency, n (%) * | 24 (55) | 2 (15) | 26 (33) | 0.0069 |
| HVS culture, n (%) | ||||
| Fully susceptible | 31 (54) | 2 (10) | 33 (42) | - |
| Azole-resistant | 13 (23) | 2 (10) | 15 (19) | - |
| No growth | 12 (21) | 17 (80) | 29 (37) | - |
| Result not available | 2 (1) | 0 (0) | 2 (3) | - |
| Management in clinic, n (%) | ||||
| Skin care advice | 57 (100) | 21 (100) | 78 (100) | - |
| Topical oestrogen | 6 (11) | 1 (5) | 7 (9) | - |
| Topical steroids | 5 (9) | 3 (14) | 8 (10) | - |
| Antihistamine | 5 (9) | 5 (24) | 10 (13) | - |
| Antifungal therapy prescribed at clinic, n (%) | ||||
| Acute | 0 (0) | 9 (43) | 9 (12) | - |
| Single-agent suppression | 53 (93) | 2 (10) | 55 (71) | - |
| Combination suppression | 4 (7) | 0 (0) | 4 (5) | - |
| Off-license | 32 (56) | 10 (47) | 42 (54) | - |
| Clinical response, n (%) | ||||
| Good | 47 (82) | 12 (57) | 62 (79) | - |
| Partial | 9 (16) | 5 (24) | 14 (18) | - |
| Poor | 0 (0) | 2 (10) | 2 (3) | - |
| Not available | 1 (2) | 2 (10) | 3 (4) | - |
* Test performed by ELISA at the Immunology Department of the Great Ormond Street Hospital in London, UK.